Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
Hepatitis B virus
antibody to hepatitis B core antigen
blood safety
hemovigilance
hepatitis C virus
human immunodeficiency virus type 1
nucleic acid amplification technique
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
27
06
2018
revised:
06
02
2019
accepted:
12
02
2019
pubmed:
24
4
2019
medline:
18
10
2019
entrez:
24
4
2019
Statut:
ppublish
Résumé
In Germany, in addition to standard blood donor screening, further mandatory tests were introduced for HCV-RNA, HIV-1-RNA and for anti-HBc. Screening for HBV-DNA is optional. This study investigates the benefits of these additional tests for the detection of HIV, HCV, and HBV infections among German blood donors. From 2008 to 2015 we collected data on blood donations exclusively testing NAT positive (NAT yield) or reactive in only one of the screening assays. Assuming a Poisson distribution, we calculated NAT yield/reactive only rates on a per donation basis (number of yield/reactive only cases divided by the number of donations tested in the period under review) with 95% confidence intervals. Responding establishments covered 95% of the donations. We identified 20 HIV-1-NAT, 61 HCV-NAT and 29 HBV-NAT yield cases among approximately 46 million blood donations tested corresponding to 0·43 HIV-1 NAT, 1·32 HCV-NAT, and 0·64 HBV-NAT yield cases per million blood donations tested. For one HBsAg reactive only case and 23 anti-HBc reactive only cases in repeat donors, infection was confirmed by ID-NAT which translates into 0·02 and 0·55 cases per million donations tested. During the 8-year-observation period, one HIV-1, no HCV and four HBV transmissions associated with donations in the viremic pre-seroconversion window period were reported. Annually, NAT screening alone detected 2·5 HIV-1, 7·6 HCV, and 3·6 HBV infectious donations; anti-HBc screening alone identified 2·9 infectious donations of repeat donors with occult HBV infection. Overall, the survey results support that the currently practiced donor HIV/HCV/HBV screening strategy in Germany does ensure a high standard of blood safety.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
In Germany, in addition to standard blood donor screening, further mandatory tests were introduced for HCV-RNA, HIV-1-RNA and for anti-HBc. Screening for HBV-DNA is optional. This study investigates the benefits of these additional tests for the detection of HIV, HCV, and HBV infections among German blood donors.
MATERIALS AND METHODS
METHODS
From 2008 to 2015 we collected data on blood donations exclusively testing NAT positive (NAT yield) or reactive in only one of the screening assays. Assuming a Poisson distribution, we calculated NAT yield/reactive only rates on a per donation basis (number of yield/reactive only cases divided by the number of donations tested in the period under review) with 95% confidence intervals.
RESULTS
RESULTS
Responding establishments covered 95% of the donations. We identified 20 HIV-1-NAT, 61 HCV-NAT and 29 HBV-NAT yield cases among approximately 46 million blood donations tested corresponding to 0·43 HIV-1 NAT, 1·32 HCV-NAT, and 0·64 HBV-NAT yield cases per million blood donations tested. For one HBsAg reactive only case and 23 anti-HBc reactive only cases in repeat donors, infection was confirmed by ID-NAT which translates into 0·02 and 0·55 cases per million donations tested. During the 8-year-observation period, one HIV-1, no HCV and four HBV transmissions associated with donations in the viremic pre-seroconversion window period were reported.
CONCLUSION
CONCLUSIONS
Annually, NAT screening alone detected 2·5 HIV-1, 7·6 HCV, and 3·6 HBV infectious donations; anti-HBc screening alone identified 2·9 infectious donations of repeat donors with occult HBV infection. Overall, the survey results support that the currently practiced donor HIV/HCV/HBV screening strategy in Germany does ensure a high standard of blood safety.
Identifiants
pubmed: 31012114
doi: 10.1111/vox.12770
pmc: PMC6849742
doi:
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Core Antigens
0
Hepatitis B Surface Antigens
0
Uronic Acids
0
N-acetyltalosaminuronic acid
90319-06-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-450Informations de copyright
© 2019 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Transfus Clin Biol. 2017 Sep;24(3):182-188
pubmed: 28709845
Virol J. 2016 Mar 05;13:36
pubmed: 26944046
Transfusion. 2014 Aug;54(8):2084-91
pubmed: 24650170
Transfusion. 2009 Sep;49(9):1850-8
pubmed: 19453976
Comput Biol Med. 1992 Sep;22(5):351-61
pubmed: 1424580
Transfusion. 2009 Feb;49(2):301-10
pubmed: 19389212
Transfusion. 2018 Sep;58(9):2166-2170
pubmed: 30144082
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Aug;55(8):907-13
pubmed: 22842883
Transfusion. 2002 Aug;42(8):980-8
pubmed: 12385407
Transfusion. 2016 Dec;56(12):3101-3111
pubmed: 27696441
Euro Surveill. 2005 Feb;10(2):9-10
pubmed: 29183543
J Clin Virol. 2006 May;36 Suppl 1:S23-9
pubmed: 16831689
Vox Sang. 2008 May;94(4):267-76
pubmed: 18179678
Transfusion. 2017 Jan;57(1):24-35
pubmed: 27673757
Transfusion. 2012 Mar;52(3):478-88
pubmed: 21880046
Vox Sang. 2012 Jan;102(1):82-90
pubmed: 21933190